Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Gujarat Themis Biosyn
Small Cap•221 Employees•IPO 1993
Current Price
₹269.50
-11.45 (-4.08%)Updated
Today's Range
269.05
₹269.50
283.8
52 Week Range
52W Low₹222.05
52W High₹479.00
₹269.50
Downside21.37%
Upside77.74%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹3,668 Cr
Market Cap
Total market value of companyP/E Ratio
75.96
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
16.27
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹4.43
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
10.24%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
27.30%
ROCE
Return on Capital Employed. >15% is goodNet Margin
31.06%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-22.77%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
12.12%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-7.62%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-31.60%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.12
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹22.79
Book Value
Net asset value per shareDividend Yield
0.20%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
70.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •The company demonstrates robust profitability with an impressive Return on Capital Employed (ROCE) of 27.30% and Return on Equity (ROE) of 21.70%, indicating efficient capital utilization and strong shareholder returns.
- •Gujarat Themis Biosyn maintains a very healthy financial structure, evidenced by its low Debt-to-Equity ratio of 0.12, suggesting minimal reliance on borrowed funds and strong financial stability.
Weaknesses
4 points- •The stock trades at a very high Price-to-Earnings (P/E) ratio of 113.00, significantly above industry peers, suggesting potential overvaluation and limited upside at current levels.
- •The company reported a notable decline in recent quarterly sales by -7.62% and a substantial drop in net profit by -31.60%, raising concerns about short-term operational challenges.
Opportunities
3 points- •Operating in the Pharmaceuticals industry, the company can capitalize on the inherent growth trends, increasing healthcare demand, and innovation opportunities within this resilient sector.
- •The consistent increase in FII holdings from 0.00% in 2022 to 2.95% in 2025, alongside DII growth, indicates a broadening institutional investor base, potentially enhancing liquidity and market visibility.
Threats
3 points- •The company faces significant competitive pressure from much larger and established players in the pharmaceutical sector, such as Sun Pharma and Divi's Lab, with vastly superior resources and market reach.
- •The overall Pharmaceuticals sector P/E of 329.35 suggests a highly valued industry, posing a risk of sector-wide correction that could negatively impact the company's stock performance.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹308.68 | +₹39.18 | +14.54% |
| R3 | ₹293.93 | +₹24.43 | +9.07% |
| R2 | ₹288.87 | +₹19.37 | +7.19% |
| R1 | ₹279.18 | +₹9.68 | +3.59% |
| PIVOT | ₹274.12 | 4.62 | 1.71% |
| CURRENT | ₹269.50 | - | - |
| S1 | ₹234.93 | -₹34.57 | -12.83% |
| S2 | ₹249.68 | -₹19.82 | -7.35% |
| S3 | ₹259.37 | -₹10.13 | -3.76% |
| S4 | ₹264.43 | -₹5.07 | -1.88% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+18.1% vs avg
0.91L
(13 Mar 2026)Delivery %+14.6% vs avg
67.7%
(13 Mar 2026)Avg Volume (20D)20-day average
0.77L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
53.1%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Shilpa Medicare Ltd
234.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %
Peer Comparison
| Company Name |
|---|
 Aarti Drugs Ltd |
 Aarti Pharmalabs Ltd |
 Blue Jet Healthcare Ltd |
 FDC Ltd |
 Gufic BioSciences Ltd |
 Orchid Pharma Ltd |
 RPG Life Sciences Ltd |
 Senores Pharmaceuticals Ltd |
 Sequent Scientific Ltd |
 Shilpa Medicare Ltd |
 SMS Pharmaceuticals Ltd |
 Sun Pharma Advanced Research Company Ltd |
 Sun Pharmaceutical Industries Ltd |
 Supriya Lifescience Ltd |
 Unichem Laboratories Ltd |
 Zota Health Care Ltd |
About
Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Limited (GUJTHEM) is an Indian pharmaceutical company specializing in the manufacturing of pharmaceuticals and medicinal chemicals. Its primary operations are focused within India, contributing to the domestic pharmaceutical market.
A significant part of GUJTHEM's business model involves providing bulk drug manufacturing services on a job work basis. This means the company produces active pharmaceutical ingredients (APIs) for other pharmaceutical companies, acting as a contract manufacturer rather than solely focusing on producing and selling its own branded products. This outsourcing model allows GUJTHEM to leverage its manufacturing capabilities to serve a broader range of clients.
The company's product portfolio includes several key APIs, highlighting its expertise in specific therapeutic areas. Rifamycin-S, an intermediate used in the creation of tuberculosis treatments, is a prominent example. The production of Rifamycin-O, another important intermediate, also features prominently. Lovastatin, a cholesterol-lowering drug, represents another significant product within GUJTHEM's range. This diverse product mix showcases the company's capabilities in producing different types of APIs for various pharmaceutical applications.
Established in 1981 and headquartered in Mumbai, GUJTHEM has a long history in the Indian pharmaceutical industry. Its long operational history suggests a degree of experience and established manufacturing processes. The location in Mumbai positions it strategically within a major economic and industrial hub of India, facilitating access to resources, talent, and markets.
COMPANY FACTS - GUJTHEM
Registered Address
Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West)
Mumbai
MAHARASHTRA
IN
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: BSE LTD
Employees: 221
IPO Date: 13/07/1993
MANAGEMENT - GUJTHEM
Dr. Dinesh Patel
Non-Executive Chairman of the Board
Mr. Tapas Thakurata
Chief Executive Officer
Mr. Bhavik Shah
Interim Chief Financial Officer
Mr. Kim Do-Deon
Chief Technical Officer
Mr. Vineet Gawankar
Chief Compliance Officer, Company Secretary
Dr. Sachin Patel
Non-Executive Director
Mr. K. G. Ananthakrishnan
Additional Non-Executive Independent Director
Mr. Hitesh Gajorio
Additional Non-Executive Independent Director
Mr. Siddharth Kusumgar
Non-Executive Independent Director
Mrs. Kirandeep Madan
Non-Executive Independent Woman Director
Investor Questions Answered
Gujarat Themis Biosyn Ltd (GUJTHEM) Stock FAQs
Get answers to the most common questions about Gujarat Themis Biosyn Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹269.5. Today, the stock has declined by ₹11.45 (4.08%), trading in a range of ₹269.05 to ₹283.8. The stock opened at ₹278.15 with a trading volume of 15,669 shares.
Gujarat Themis Biosyn Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,668 crores, P/E ratio of 75.96, ROE of 10.24%, and ROCE of 27.30%. The dividend yield stands at 0.20%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹479, while the 52-week low is ₹222.05. Currently trading at ₹269.5, the stock is 18.5% away from its 52-week low and 43.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Gujarat Themis Biosyn Ltd stock at ₹269.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 75.96 and P/B ratio of N/A. Today's performance shows a loss of 4.08%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Gujarat Themis Biosyn Ltd offers a dividend yield of 0.20%, which means for every ₹100 invested at the current price of ₹269.5, you can expect to receive approximately ₹0.20 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Gujarat Themis Biosyn Ltd's key financial metrics include: P/E Ratio: 75.96, P/B Ratio: N/A, ROE: 10.24%, ROCE: 27.30%, Dividend Yield: 0.20%, EPS: ₹4.43, Book Value: ₹22.79, Debt-to-Equity: 0.12, and Current Ratio: N/A. The company's market cap stands at ₹3,668 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Gujarat Themis Biosyn Ltd stock opened at ₹278.15 and is currently trading at ₹269.5, showing a decline of ₹11.45 (4.08%). The intraday high is ₹283.8 and low is ₹269.05. The trading volume stands at 15,669 shares, indicating moderate market participation today.
Gujarat Themis Biosyn Ltd has a Price-to-Earnings (P/E) ratio of 75.96, which means investors are willing to pay ₹75.96 for every ₹1 of earnings. With an EPS of ₹4.43, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Gujarat Themis Biosyn Ltd has a market capitalization of ₹3,668 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹269.5) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Gujarat Themis Biosyn Ltd has a book value of ₹22.79 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹269.5, which is 1082.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Gujarat Themis Biosyn Ltd has a Return on Equity (ROE) of 10.24% and Return on Capital Employed (ROCE) of 27.30%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Gujarat Themis Biosyn Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Gujarat Themis Biosyn Ltd has a debt-to-equity ratio of 0.12, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Gujarat Themis Biosyn Ltd has an Earnings Per Share (EPS) of ₹4.43, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹269.5 and P/E ratio of 75.96, investors are paying 75.96 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Gujarat Themis Biosyn Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Gujarat Themis Biosyn Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Gujarat Themis Biosyn Ltd stock, consider: 1) Fundamental Analysis - Review P/E (75.96), ROE (10.24%), debt-to-equity (0.12), and growth rates. 2) Technical Analysis - Check 52-week range (₹222.05 - ₹479.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹269.50) with book value (₹22.79) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Gujarat Themis Biosyn Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹269.5 is 26850x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Gujarat Themis Biosyn Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹222.05 - ₹479.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.12 indicates leverage. 4) Liquidity Risk - Based on trading volume of 15,669 shares. 5) Valuation Risk - P/E of 75.96 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Gujarat Themis Biosyn Ltd operates in the industry with key metrics: P/E ratio of 75.96, ROE of 10.24%, market cap of ₹3,668 crores, and dividend yield of 0.20%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.12), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Gujarat Themis Biosyn Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹269.5, with a 52-week range of ₹222.05 to ₹479.00. Based on fundamentals like P/E (75.96), ROE (10.24%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Gujarat Themis Biosyn Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹269.50. 2) Fundamental Deterioration - Declining ROE (currently 10.24%), increasing debt (D/E: 0.12), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Gujarat Themis Biosyn Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.20%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu